AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:
Maria E. Arcila, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Bristol-Myers Squibb Co, AstraZeneca Pharmaceuticals LP, and Janssen Oncology. Serve(d) as a speaker or a member of a speakers bureau for: Biocartis and Invivoscribe. Alexander Drilon, MD, reported a financial interest/relationship or affiliation in the form of Advisory board: Roche/Genentech/Ignyta; Loxo/Bayer/Lilly; Takeda Oncology/Ariad/Millenium; Turning Point Therapeutics, Inc; AstraZeneca Pharmaceuticals LP; Pfizer, Inc; Blueprint Medicines; Helsinn Therapeutics (US) Inc; BeiGene LTD; BerGenBio; Hengrui Therapeutics, Inc; Exelixis, Inc; Tyra Biosciences; Verastem Inc; MORE Health; and AbbVie. Research grant: Foundation Medicine. Research support to Memorial Sloan Kettering Cancer Center: Pfizer, Inc; Exelixis, Inc; GlaxoSmithKline; Teva Pharmaceuticals; Taiho Pharmaceutical Co, Ltd; and Pharma Mar, S.A. Royalty: Wolters Kluwer. Other, Food and Beverage: Merck & Co, Inc and PUMA Biotechnology.
The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.